WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 314203
CAS#: 842133-18-0 (free)
Description: Canagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. In March 2013, canagliflozin became the first SGLT2 inhibitor to be approved in the United States.
MedKoo Cat#: 314203
Name: Canagliflozin
CAS#: 842133-18-0 (free)
Chemical Formula: C24H25FO5S
Exact Mass: 444.14067
Molecular Weight: 444.52
Elemental Analysis: C, 64.85; H, 5.67; F, 4.27; O, 18.00; S, 7.21
Related CAS #: 928672-86-0 (hemihydrate) 842133-18-0 (free)
Synonym: JNJ 24831754; INJ24831754; JNJ-24831754; JNJ24831754AAA; JNJ24831754ZAE; TA 7284; TA-7284; TA7284; Canagliflozin; Trade name: Invokana.
IUPAC/Chemical Name: (3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
InChi Key: XTNGUQKDFGDXSJ-KKEQRHKBSA-N
InChi Code: InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24?/m1/s1
SMILES Code: O[C@H]1C(C2=CC=C(C)C(CC3=CC=C(C4=CC=C(F)C=C4)S3)=C2)O[C@H](CO)[C@@H](O)[C@@H]1O
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively. |
| In vitro activity: | To understand the mechanism of Cana (Canagliflozin) regulated Abcg5 and Abcg8 expression, this study explored the signaling pathway. Cana has been reported to activate AMPK in several cell lines. In hepG2 cells, Cana could directly activate AMPK and its downstream phosphorylation of ACC (Figure 4B). In Caco2 cells, AMPK was also activated by Cana treatment (Figure 4C). To confirm whether Cana regulated Abcg5 and Abcg8 was AMPK dependent, this study treated hepG2 and Caco2 cells with compound C, a pharmacological inhibitor of AMPK. Inhibition of AMPK pathway abolished Cana increased expression of Abcg5 and Abcg8 in both hepG2 and Caco2 cells (Figure 5A–F, Supplementary Figure 6A–F). Cana upregulated expressions of LXR in both hepG2 and Caco2 cells were also inhibited by Compound C (Supplementary Figure 6G and H). Taken together, Cana increased Abcg5 and Abcg8 expression via activating AMPK pathway. Reference: Drug Des Devel Ther. 2021 May 18;15:2117-2128. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140894/ |
| In vivo activity: | In this study, CAN (Canagliflozin) significantly improved acute lung injures induced by LPS (increased lung edema and lung capillary penetration) in mice. The pathological slice results also indicated this improvement. Immunohistochemistry analysis further indicated that CAN attenuated macrophage (identified by CD11b antibody) infiltration in lung tissues induced by LPS, which may be associated with the decreased chemotactic cytokines, for example, MCP-1 and MIP-2 in lung tissues of mice. In blood samples, CAN significantly reduced the inflammatory factors, which suggested that CAN had a systematic inhibition on immune cell activation in vivo after acute treatment. Although this study used CAN or DXM (Dexamethasone) only for 3 days, more COVID-19 patients may require longer administration of these anti-inflammatory drugs and a safety concern could be considered. In a preliminary experiment, chronic administration (about 3 months) of CAN (25 mg/kg) did not affect the spleen weight in mice compared with untreated controls, whereas 1-month administration of dexamethasone (2 mg/kg) significantly lowered the spleen weight in mice (supplemental Fig. 1) compared with untreated controls. These results indicated that CAN might not significantly affect immune organ development similar to glucocorticoids if patients required a long-term administration. Reference: Int Immunopharmacol. 2021 Jul; 96: 107773. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106881/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 69.5 | 156.35 |
The following data is based on the product molecular weight 444.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Zhao Y, Li Y, Liu Q, Tang Q, Zhang Z, Zhang J, Huang C, Huang H, Zhang G, Zhou J, Yan J, Xia Y, Zhang Z, He J. Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway. Drug Des Devel Ther. 2021 May 18;15:2117-2128. doi: 10.2147/DDDT.S306367. PMID: 34040350; PMCID: PMC8140894. 2. Papadopoli D, Uchenunu O, Palia R, Chekkal N, Hulea L, Topisirovic I, Pollak M, St-Pierre J. Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. Neoplasia. 2021 Apr;23(4):391-399. doi: 10.1016/j.neo.2021.02.003. Epub 2021 Mar 27. PMID: 33784591; PMCID: PMC8027095. 3. Niu Y, Chen Y, Sun P, Wang Y, Luo J, Ding Y, Xie W. Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: A potential COVID-19 treatment. Int Immunopharmacol. 2021 May 9;96:107773. doi: 10.1016/j.intimp.2021.107773. Epub ahead of print. PMID: 34020392; PMCID: PMC8106881. 4. Nishinarita R, Niwano S, Niwano H, Nakamura H, Saito D, Sato T, Matsuura G, Arakawa Y, Kobayashi S, Shirakawa Y, Horiguchi A, Ishizue N, Igarashi T, Yoshizawa T, Oikawa J, Hara Y, Katsumura T, Kishihara J, Satoh A, Fukaya H, Sakagami H, Ako J. Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model. J Am Heart Assoc. 2021 Jan 19;10(2):e017483. doi: 10.1161/JAHA.119.017483. Epub 2021 Jan 5. PMID: 33399004; PMCID: PMC7955321. |
| In vitro protocol: | 1. Zhao Y, Li Y, Liu Q, Tang Q, Zhang Z, Zhang J, Huang C, Huang H, Zhang G, Zhou J, Yan J, Xia Y, Zhang Z, He J. Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway. Drug Des Devel Ther. 2021 May 18;15:2117-2128. doi: 10.2147/DDDT.S306367. PMID: 34040350; PMCID: PMC8140894. 2. Papadopoli D, Uchenunu O, Palia R, Chekkal N, Hulea L, Topisirovic I, Pollak M, St-Pierre J. Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. Neoplasia. 2021 Apr;23(4):391-399. doi: 10.1016/j.neo.2021.02.003. Epub 2021 Mar 27. PMID: 33784591; PMCID: PMC8027095. |
| In vivo protocol: | 1. Niu Y, Chen Y, Sun P, Wang Y, Luo J, Ding Y, Xie W. Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: A potential COVID-19 treatment. Int Immunopharmacol. 2021 May 9;96:107773. doi: 10.1016/j.intimp.2021.107773. Epub ahead of print. PMID: 34020392; PMCID: PMC8106881. 2. Nishinarita R, Niwano S, Niwano H, Nakamura H, Saito D, Sato T, Matsuura G, Arakawa Y, Kobayashi S, Shirakawa Y, Horiguchi A, Ishizue N, Igarashi T, Yoshizawa T, Oikawa J, Hara Y, Katsumura T, Kishihara J, Satoh A, Fukaya H, Sakagami H, Ako J. Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model. J Am Heart Assoc. 2021 Jan 19;10(2):e017483. doi: 10.1161/JAHA.119.017483. Epub 2021 Jan 5. PMID: 33399004; PMCID: PMC7955321. |
1: Davidson JA, Sloan L. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Adv Ther. 2016 Nov 16. [Epub ahead of print] Review. PubMed PMID: 27854055.
2: Qiu R, Balis D, Capuano G, Xie J, Meininger G. Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes. Diabetes Ther. 2016 Oct 12. [Epub ahead of print] Review. PubMed PMID: 27734320.
3: Canagliflozin (Invokana) for Type 2 Diabetes Mellitus [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Sep. Available from http://www.ncbi.nlm.nih.gov/books/NBK349575/ PubMed PMID: 26962611.
4: Kaur K, Likar N, Dang A, Kaur G. Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Indian J Endocrinol Metab. 2015 Nov-Dec;19(6):705-21. doi: 10.4103/2230-8210.167562. Review. PubMed PMID: 26693420; PubMed Central PMCID: PMC4673798.
5: Parveen R, Agarwal NB, Kaushal N, Mali G, Raisuddin S. Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Expert Opin Pharmacother. 2016;17(1):105-15. doi: 10.1517/14656566.2016.1109629. Review. PubMed PMID: 26650511.
6: Seufert J. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes. 2015 Nov 9;8:543-54. doi: 10.2147/DMSO.S90662. Review. PubMed PMID: 26609242; PubMed Central PMCID: PMC4644173.
7: Syed SH, Gosavi S, Shami W, Bustamante M, Farah Z, Teleb M, Abbas A, Said S, Mukherjee D. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin. Cardiovasc Hematol Agents Med Chem. 2015;13(2):105-12. Review. PubMed PMID: 26549321.
8: Triplitt C, Cornell S. Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. Clin Med Insights Endocrinol Diabetes. 2015 Oct 18;8:73-81. doi: 10.4137/CMED.S31526. Review. PubMed PMID: 26523120; PubMed Central PMCID: PMC4610726.
9: Perkovic V, Jardine M, Vijapurkar U, Meininger G. Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin. 2015 Dec;31(12):2219-31. doi: 10.1185/03007995.2015.1092128. Review. PubMed PMID: 26494163.
10: Rosenthal N, Meininger G, Ways K, Polidori D, Desai M, Qiu R, Alba M, Vercruysse F, Balis D, Shaw W, Edwards R, Bull S, Di Prospero N, Sha S, Rothenberg P, Canovatchel W, Demarest K. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015 Nov;1358:28-43. doi: 10.1111/nyas.12852. Review. PubMed PMID: 26305874.
11: Fleming JW, Fleming LW, Davis CS. Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination. Diabetes Metab Syndr Obes. 2015 Jun 25;8:287-94. doi: 10.2147/DMSO.S69282. Review. PubMed PMID: 26150733; PubMed Central PMCID: PMC4485795.
12: Patel S, Gohel K, Patel BG. A Systematic Review on Effect of Canagliflozin in Special Population. Curr Diabetes Rev. 2016;12(3):211-22. Review. PubMed PMID: 26084476.
13: Devineni D, Polidori D. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Clin Pharmacokinet. 2015 Oct;54(10):1027-41. doi: 10.1007/s40262-015-0285-z. Review. PubMed PMID: 26041408.
14: Scheen AJ. [Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes]. Rev Med Liege. 2014 Dec;69(12):692-9. Review. French. PubMed PMID: 25796788.
15: Khurana M, Vaidyanathan J, Marathe A, Mehrotra N, Sahajwalla CG, Zineh I, Jain L. Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization. J Clin Pharmacol. 2015 Jun;55(6):647-56. doi: 10.1002/jcph.466. Review. PubMed PMID: 25612234.
16: Amblee A. Patient profiling in diabetes and role of canagliflozin. Pharmgenomics Pers Med. 2014 Nov 18;7:367-77. doi: 10.2147/52761.S0. Review. PubMed PMID: 25540592; PubMed Central PMCID: PMC4270036.
17: Sehgal V, Bajwa SJ, Sehgal R, Consalvo JA. Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon. J Pharmacol Pharmacother. 2014 Oct;5(4):227-31. doi: 10.4103/0976-500X.142428. Review. Erratum in: J Pharmacol Pharmacother. 2015 Jan-Mar;6(1):58. PubMed PMID: 25422561; PubMed Central PMCID: PMC4231550.
18: Boyle LD, Wilding JP. A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes. Expert Opin Drug Saf. 2014 Nov;13(11):1535-44. doi: 10.1517/14740338.2014.959488. Review. PubMed PMID: 25340618.
19: Brunton S, Reid TS. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes. Hosp Pract (1995). 2014 Aug;42(3):96-108. doi: 10.3810/hp.2014.08.1122. Review. PubMed PMID: 25255411.
20: Rosiak M, Grzeszczak S, Kosior DA, Postuła M. Emerging treatments in type 2 diabetes: focus on canagliflozin. Ther Clin Risk Manag. 2014 Aug 21;10:683-9. doi: 10.2147/TCRM.S39145. Review. PubMed PMID: 25187722; PubMed Central PMCID: PMC4149387.
Related CAS#
842133-18-0 (Canagliflozin)
928672-86-0 (Canagliflozin hemihydrate)
